Humacyte Inc
NASDAQ:HUMA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
A
|
Alta SA
WSE:AAT
|
PL |
|
Armadale Capital PLC
LSE:ACP
|
UK |
|
Renascor Resources Ltd
ASX:RNU
|
AU |
|
I
|
Invictus Energy Ltd
OTC:IVCTF
|
AU |
|
T
|
Tasco JSC
VN:HUT
|
VN |
|
J
|
JES International Holdings Ltd
SGX:EG0
|
CN |
|
P
|
Pelayaran Nasional Ekalya Purnamasari Tbk PT
IDX:ELPI
|
ID |
|
TYK Corp
TSE:5363
|
JP |
|
C
|
Caterpillar Inc
SWB:CAT1
|
US |
Humacyte Inc
Total Equity
Humacyte Inc
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Humacyte Inc
NASDAQ:HUMA
|
Total Equity
-$52.7m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Total Equity
-$3.3B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Total Equity
$22.7B
|
CAGR 3-Years
2%
|
CAGR 5-Years
5%
|
CAGR 10-Years
2%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Total Equity
$8.7B
|
CAGR 3-Years
33%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-11%
|
|
|
Exact Sciences Corp
NASDAQ:EXAS
|
Total Equity
$2.4B
|
CAGR 3-Years
-8%
|
CAGR 5-Years
1%
|
CAGR 10-Years
22%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Total Equity
$18.7B
|
CAGR 3-Years
10%
|
CAGR 5-Years
17%
|
CAGR 10-Years
35%
|
|
Humacyte Inc
Glance View
Humacyte, Inc. engages in the manufacture of human acellular matrix products for vascular and non-vascular applications. The company is headquartered in Durham, North Carolina and currently employs 145 full-time employees. The company went IPO on 2020-09-22. The company is developing a portfolio of human acellular vessels (HAVs) with varying diameters and lengths. The HAV cabinet would initially target the vascular repair, reconstruction and replacement market, including vascular trauma; atrioventricular (AV) access for hemodialysis; peripheral arterial disease (PAD); and coronary artery bypass grafting (CABG). The firm has developed a paradigm for manufacturing human tissues that is intended to mimic key aspects of human physiology. The company is developing and manufacturing acellular tissues to address life- and limb-threatening vascular conditions while focusing on potential future applications for complex tissue and organ diseases. The company is also engaged in developing its HAVs for pediatric heart surgery and the delivery of cellular therapies, including pancreatic islet cell transplantation to treat Type 1 diabetes.
See Also
What is Humacyte Inc's Total Equity?
Total Equity
-52.7m
USD
Based on the financial report for Dec 31, 2024, Humacyte Inc's Total Equity amounts to -52.7m USD.
